Entering text into the input field will update the search result below

Global Blood's GBT440 nabs Rare Pediatric Disease tag in U.S.

Sep. 05, 2017 3:18 PM ETPfizer Inc. (PFE) StockBy: Douglas W. House, SA News Editor6 Comments
  • The FDA designates Global Blood Therapeutics' (NASDAQ:GBT -4.6%) lead product candidate GBT440 for Rare Pediatric Disease status for the treatment of sickle cell disease (SCD). The designation allows the company to receive a Priority Review voucher, if GBT440 is approved for the indication, that can be used for accelerated review of a future marketing application or it can be sold to a third party.
  • GBT440 also has Orphan Drug and Fast Track status in the U.S.
  • Previously: Enrollment underway in late-stage study assessing Global Blood's GBT440 in sickle cell disease (Jan. 20)

Recommended For You

About PFE Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
PFE--
Pfizer Inc.